The bet on PET: detecting liver lesions is not enough

Affiliations

¹ Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: marcus.hacker@meduniwien.ac.at.

Comment

Marcus Hacker. Lancet Gastroenterol Hepatol. 2025 Apr.

. 2025 Apr;10(4):277-278.

doi: 10.1016/S2468-1253(25)00023-8. Epub 2025 Feb 20.

¹ Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: marcus.hacker@meduniwien.ac.at.

No abstract available

Conflict of interest statement

I declare no competing interests.

[¹⁸F]fluorodeoxyglucose and [¹⁸F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study.
Nault JC, Boubaya M, Wartski M, Dohan A, Pol S, Pop G, Soussan M, Sutter O, Costentin C, Roux J, Sengel C, Lequoy M, Montravers F, Menu Y, Pageaux GP, Goulart DM, Guiu B, Luciani A, Nahon P, Dioguardi Burgio M, Wagner M, Maksud P, Mulé S, Allaire M, Sidali S, Coilly A, Besson FL, Lewin M, Regnault H, Hollande C, Amaddeo G, Ronot M, Ganne-Carrié N, Itti E, Bloch-Queyrat C, Levy V, Lebtahi R, Chalaye J, Bouattour M. Nault JC, et al. Lancet Gastroenterol Hepatol. 2025 Apr;10(4):306-314. doi: 10.1016/S2468-1253(25)00011-1. Epub 2025 Feb 20. Lancet Gastroenterol Hepatol. 2025. PMID: 39987937 Clinical Trial.